Pancreatic cancers: New drug doubles survival rate as France rolls out prevention program

In cases of metastatic pancreatic tumors, daraxonrasib has been shown to drastically increase survival rates, according to an international trial presented at the American Society of Clinical Oncology congress on Sunday.

In France, a personalized screening and prevention program, launched by the Gustave-Roussy Institute has been extended to eight additional centers. ...